• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

导致良性前列腺增生患者服用西洛多辛后主观症状改善失败的因素有哪些?应用压力-流率研究进行的调查。

What are the factors contributing to failure in improvement of subjective symptoms following silodosin administration in patients with benign prostatic hyperplasia? Investigation using a pressure-flow study.

机构信息

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

出版信息

Neurourol Urodyn. 2013 Mar;32(3):266-70. doi: 10.1002/nau.22286. Epub 2012 Aug 20.

DOI:10.1002/nau.22286
PMID:22907775
Abstract

AIMS

To investigate the factors responsible for failure in improvement of subjective symptoms following silodosin treatment on the basis of findings of a pressure-flow study (PFS).

METHODS

A post hoc analysis of a prospective study to investigate the efficacy of silodosin in patients with BPH was conducted, and 104 patients were analyzed. The patients were administered silodosin 8 mg/day for 4 weeks. At the baseline and after treatment, subjective symptoms were evaluated using the IPSS and OABSS. A PFS was conducted to measure storage and voiding function. The patients were divided into two groups: good responders (GR), patients with 25% or more improvement in IPSS, and poor responders (PR), <25% improvement. The clinical and objective findings for the two groups were compared.

RESULTS

The mean IPSS and OABSS significantly improved in GR, but no significant improvement was observed in PR. PFS analysis revealed that all voiding and storage function parameters improved significantly in GR. Although PR showed a significant improvement in the voiding function parameters, it did not show significant changes in the storage function. Involuntary detrusor contraction (IDC) resolved in 68.6% of the patients in GR and in only 30% of the patients in PR, thereby showing a significant difference in the remedial effect between the two groups.

CONCLUSIONS

The findings suggest that insufficient improvement in storage function is a contributing factor to the failure in improvement of subjective symptoms after silodosin treatment in patients with BPH.

摘要

目的

基于压力-流研究(PFS)的结果,探讨在接受西洛多辛治疗后主观症状改善失败的原因。

方法

对一项前瞻性研究治疗 BPH 患者的西洛多辛疗效的事后分析,共分析了 104 例患者。患者接受西洛多辛 8mg/天治疗 4 周。在基线和治疗后,使用 IPSS 和 OABSS 评估主观症状。进行 PFS 以测量储存和排尿功能。将患者分为两组:良好反应组(GR),IPSS 改善 25%或更多的患者;和差反应组(PR),改善<25%的患者。比较两组的临床和客观发现。

结果

GR 的平均 IPSS 和 OABSS 显著改善,但 PR 没有显著改善。PFS 分析显示,GR 的所有排尿和储存功能参数均显著改善。尽管 PR 的排尿功能参数有显著改善,但储存功能没有显著变化。GR 中 68.6%的患者逼尿肌不自主收缩(IDC)得到缓解,而 PR 中只有 30%的患者得到缓解,因此两组的缓解效果有显著差异。

结论

研究结果表明,储存功能改善不足是 BPH 患者接受西洛多辛治疗后主观症状改善失败的一个原因。

相似文献

1
What are the factors contributing to failure in improvement of subjective symptoms following silodosin administration in patients with benign prostatic hyperplasia? Investigation using a pressure-flow study.导致良性前列腺增生患者服用西洛多辛后主观症状改善失败的因素有哪些?应用压力-流率研究进行的调查。
Neurourol Urodyn. 2013 Mar;32(3):266-70. doi: 10.1002/nau.22286. Epub 2012 Aug 20.
2
Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia.治疗良性前列腺增生的新型α1A-肾上腺素能受体选择性拮抗剂——西洛多辛的尿动力学效应。
Neurourol Urodyn. 2010 Apr;29(4):558-62. doi: 10.1002/nau.20802.
3
Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).西洛多辛与坦索罗辛治疗良性前列腺增生症(BPH)相关下尿路症状(LUTS)患者的非劣效性比较。
BJU Int. 2011 Dec;108(11):1843-8. doi: 10.1111/j.1464-410X.2011.10233.x. Epub 2011 May 18.
4
Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.索利那新与坦索罗辛口服控释系统单片复方制剂治疗男性储尿和排尿下尿路症状的长期安全性和疗效:NEPTUNE 研究和 NEPTUNE II 开放性扩展研究结果。
Eur Urol. 2015 Feb;67(2):262-70. doi: 10.1016/j.eururo.2014.07.013. Epub 2014 Jul 25.
5
Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.西洛多辛缓解良性前列腺梗阻的疗效:前瞻性压力流研究。
J Urol. 2013 Jan;189(1 Suppl):S117-21. doi: 10.1016/j.juro.2012.11.031.
6
Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).比较索利那新与萘哌地尔治疗良性前列腺增生症合并膀胱过度活动症的疗效:一项随机、前瞻性研究(SNIPER 研究)。
J Urol. 2017 Feb;197(2):452-458. doi: 10.1016/j.juro.2016.08.111. Epub 2016 Sep 8.
7
Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.比较萘哌地尔、坦索罗辛和西洛多辛预防 125I 近距离放射治疗前列腺癌患者下尿路症状的随机对照试验。
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e385-92. doi: 10.1016/j.ijrobp.2011.04.026. Epub 2011 Jun 12.
8
A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).一项汇总了注册试验中个体化患者数据的分析,这些试验评估了西洛多辛治疗非神经源性男性下尿路症状(LUTS)、提示良性前列腺增生(BPH)的疗效。
BJU Int. 2014 Sep;114(3):427-33. doi: 10.1111/bju.12712. Epub 2014 Mar 13.
9
Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: A randomized, prospective, comparative trial using a urodynamic study.抗胆碱能药物与α1受体阻滞剂联合治疗对同时伴有排尿困难和膀胱过度活动症症状的良性前列腺增生患者的长期疗效:一项使用尿动力学研究的随机、前瞻性对照试验。
Neurourol Urodyn. 2017 Mar;36(3):748-754. doi: 10.1002/nau.23013. Epub 2016 Apr 6.
10
Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?当前下尿路症状/BPH 的医学治疗:我们有标准吗?
Curr Opin Urol. 2014 Jan;24(1):21-8. doi: 10.1097/MOU.0000000000000007.

引用本文的文献

1
Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.坦索罗辛 8 毫克单独治疗、他达拉非 5 毫克单独治疗与两者联合治疗良性前列腺增生相关下尿路症状的前瞻性比较。
World J Urol. 2022 Aug;40(8):2063-2070. doi: 10.1007/s00345-022-04071-7. Epub 2022 Jun 30.
2
Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis.α受体阻滞剂与抗胆碱能药物初始联合治疗对下尿路症状良性前列腺增生患者的疗效及安全性:更新的荟萃分析
PLoS One. 2017 Jan 10;12(1):e0169248. doi: 10.1371/journal.pone.0169248. eCollection 2017.
3
An observational study of the use of beclomethasone dipropionate suppositories in the treatment of lower urinary tract inflammation in men.一项关于丙酸倍氯米松栓剂治疗男性下尿路感染的观察性研究。
BMC Urol. 2016 Jun 8;16(1):25. doi: 10.1186/s12894-016-0144-8.